Abbott (ABT) slips as results, guidance barely meet consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Abbott forecasts 2024 earnings largely below estimates, shares down
January 24, 2024 7:34 AM EST(Reuters) -Abbott Laboratories on Wednesday forecast 2024 profit largely below Wall Street estimates despite meeting quarterly earnings expectations, sending the medical device maker's shares down 2.5% in premarket trading.
Expectations around performance of medical device makers have increased over the last one month after health insurers flagged higher medical costs earlier this month as people, especially older adults, go back for medical procedures they had delayed during the pandemic.
Abbott's forecast also follows strong... More
Abbott (ABT) Reports In-Line Q4 EPS, Offers Guidance
January 24, 2024 7:31 AM ESTAbbott (NYSE: ABT) reported Q4 EPS of $1.19, in-line with the analyst estimate of $1.19. Revenue for the quarter came in at $10.24 billion versus the consensus estimate of $10.17 billion.
GUIDANCE:
Abbott sees FY2024 EPS of $4.50-$4.70, versus the consensus of $4.63.
For earnings history and earnings-related data on Abbott (ABT) click here.
... MoreAbbott Labs (ABT) PT Raised to $136 at UBS
January 22, 2024 7:52 AM ESTUBS analyst Danielle Antalffy raised the price target on Abbott Labs (NYSE: ABT) to $136.00 (from $122.00) while maintaining a Buy rating.... More
